Cargando…

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy

INTRODUCTION: Breast cancers of different molecular subtypes have different survival rates. The goal of this study was to identify patients at high risk for local-regional recurrence according to response to neoadjuvant chemotherapy and surrogate markers of molecular subtypes in patients undergoing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caudle, Abigail S, Yu, Tse-Kuan, Tucker, Susan L, Bedrosian, Isabelle, Litton, Jennifer K, Gonzalez-Angulo, Ana M, Hoffman, Karen, Meric-Bernstam, Funda, Hunt, Kelly K, Buchholz, Thomas A, Mittendorf, Elizabeth A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446346/ https://www.ncbi.nlm.nih.gov/pubmed/22621334 http://dx.doi.org/10.1186/bcr3198

Ejemplares similares

Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions: A Prospective, Phase IV Trial
por: Singh, Puneet, et al.
Publicado: (2020)

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
por: Le Du, Fanny, et al.
Publicado: (2015)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
por: Dominici, Laura S, et al.
Publicado: (2012)

Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome
por: Batista, Larissa I, et al.
Publicado: (2008)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
por: Meric-Bernstam, Funda, et al.
Publicado: (2012)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2015)

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
por: Skinner, Heath D, et al.
Publicado: (2013)

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2016)

High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study
por: Rosbach, Kelsey J., et al.
Publicado: (2010)

Targeting and limiting surgery for patients with node-positive breast cancer
por: Caudle, Abigail S., et al.
Publicado: (2015)

CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer
por: Aomatsu, Naoki, et al.
Publicado: (2012)

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Imaging in Locoregional Management of Breast Cancer
por: Kuhl, Christiane K., et al.
Publicado: (2020)

Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer
por: Gao, Ruli, et al.
Publicado: (2017)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Imaging the breast following neoadjuvant chemotherapy: does improvement of imaging findings in the axilla predict pathological response in the breast?
por: Williams, A, et al.
Publicado: (2012)

Functional consequence of the MET-T1010I polymorphism in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Clinical outcomes based on multigene profiling in metastatic breast cancer patients
por: Basho, Reva K., et al.
Publicado: (2016)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
por: Litton, J. K., et al.
Publicado: (2017)

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer
por: Elsayegh, Nisreen, et al.
Publicado: (2018)

Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment
por: Litton, Jennifer K., et al.
Publicado: (2010)

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes
por: Su, Xiaoping, et al.
Publicado: (2014)

Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
por: Maeshima, Yurina, et al.
Publicado: (2021)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
por: Suppan, Christoph, et al.
Publicado: (2021)

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
por: Suman, Vera J., et al.
Publicado: (2022)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

Neoadjuvant treatment for male breast cancer
por: Fentiman, Ian Stuart
Publicado: (2023)

Neoadjuvant systemic therapy for breast cancer
por: Zaborowski, Alexandra M, et al.
Publicado: (2023)

Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer
por: Kantor, Olga, et al.
Publicado: (2020)

Punctuated Copy Number Evolution and Clonal Stasis in Triple-Negative Breast Cancer
por: Gao, Ruli, et al.
Publicado: (2016)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_shojmvbk0d1vv67ouekntflem9